Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib. J Thorac Oncol. 2017 05; 12(5):804-813.
View in:
PubMed
subject areas
Antineoplastic Agents
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Carcinoma, Non-Small-Cell Lung
Disease-Free Survival
Disease-Free Survival
False Negative Reactions
False Negative Reactions
False Positive Reactions
False Positive Reactions
Female
Female
Humans
Humans
Immunohistochemistry
Immunohistochemistry
In Situ Hybridization, Fluorescence
In Situ Hybridization, Fluorescence
Lung Neoplasms
Lung Neoplasms
Male
Male
Middle Aged
Middle Aged
Observer Variation
Observer Variation
Patient Selection
Patient Selection
Pyrazoles
Pyrazoles
Pyridines
Pyridines
Receptor Protein-Tyrosine Kinases
Receptor Protein-Tyrosine Kinases
Reproducibility of Results
Reproducibility of Results
Treatment Outcome
Treatment Outcome